BNET Industries
Biogen Idec Inc. (BIIB) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $3.1B
- Profit
- Dec 31 2007
- $638.1M
- Market Cap
- Jul 23 2008
- $20.7B
Latest News and Analysis
Biogen Second-quarter Profit Rises 11 Percent
NEW YORK (Reuters) - Biogen Idec Inc BIIB, which this month fended off activist investor Carl Icahn's attempt to place three hand-picked candidates on the board, on Tuesday said second-quarter profit rose 11 percent on strong sales of its multiple sclerosis...
Roche's Genentech Offer Sends Ripples Through Biotech
Mike Huckman submits: The buyout offer from Swiss drug giant Roche (RHHBY.PK) has shares of Genentech DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, it closed at its biggest one-day percentage gain since April 15, 2005. The stock went...
Earnings Preview: Biogen Idec
Biogen Idec BIIB is expected to report Q2 earnings before market open Tuesday July 22, with a conference call scheduled for 8:30 am ET. Guidance Analysts are looking for a profit of 85c on revenue of $962.1M. The consensus is 82c to 92c for EPS, and revenue of $930M to...
Expecting Strong Upside from Biogen on Merrill Call
Notable Calls submits: Merrill Lynch upgrades Biogen-Idec BIIB to Buy from Underperform based on their assessment of the company’s earnings growth potential, an improved outlook in the multiple sclerosis [MS] market, and a diversified mid to late-stage pipeline. Applying an average biotech P/E of 19x 2009E EPS (implied PEG...
Big Biotech Booms But IBB Falls Flat
Don Dion submits: Shares in the biotech firm Amgen AMGN shot up Monday morning after the firm announced major developments for two of its products: Nplate, a drug designed to treat a rare form of blood-platelet deficiency, received final approval from the FDA, and the results of a...
Shareholders Overwhelmingly Approve Biogen Board
NEW YORK (Reuters) - Biogen Idec Inc BIIB shareholders elected the company's four-member slate of nominees to its board of directors, handily beating those proposed by billionaire investor Carl Icahn, Biogen said on Wednesday. The nominees for the biotech's board included: Cecil ...
Pfizer Makes a Deal, Wyeth and Elan Release Alzheimer's Drug Results
Mike Huckman submits: Last week, Pfizer PFE made a major announcement regarding the world's top-selling statin, Lipitor. Pfizer struck a deal with the Indian generic drugmaker Ranbaxy to ward off the threat of generic competition for Lipitor until late 2011. I know there were a lot of market pressures...
Biogen IDEC, Inc. Q1 2008 Earnings Call Transcript
Biogen IDEC, Inc. Q1 2008 Earnings Call Transcript
Biogen IDEC, Inc. Q4 2007 Earnings Call Transcript
Biogen IDEC, Inc. Q4 2007 Earnings Call Transcript
Biogen IDEC Q3 2007 Earnings Call Transcript
Biogen IDEC Q3 2007 Earnings Call Transcript
Biogen Idec Q2 2007 Earnings Call Transcript
Biogen Idec Q2 2007 Earnings Call Transcript
Biogen Idec Q1 2007 Earnings Call Transcript
Biogen Idec Q1 2007 Earnings Call Transcript
Biogen Idec Q4 2006 Earnings Call Transcript
Biogen Idec Q4 2006 Earnings Call Transcript
Biogen Idec Q3 2006 Earnings Call Transcript
Biogen Idec Q3 2006 Earnings Call Transcript
Biogen Idec Q2 2006 Earnings Conference Call Transcript (BIIB)
Biogen Idec Q2 2006 Earnings Conference Call Transcript BIIB
Biogen Idec Inc. Q1 2006 Earnings Conference Call Transcript (BIIB)
Biogen Idec Inc. Q1 2006 Earnings Conference Call Transcript BIIB
Biogen Idec Inc. Q4 2005 Earnings Conference Call Transcript (BIIB)
Biogen Idec Inc. Q4 2005 Earnings Conference Call Transcript BIIB
Full Transcript of Biogen Idecs 3Q05 Conference Call Q&A (BIIB)
Full Transcript of Biogen Idecs 3Q05 Conference Call Q&A BIIB
Full Transcript of Biogen Idecs 3Q05 Conference Call Prepared Remarks (BIIB)
Full Transcript of Biogen Idecs 3Q05 Conference Call Prepared Remarks BIIB
Additional Resources
The Board of Cigma Metals Corporation Is Pleased to Announce the Appointment of Agustin Gomez de Segura as President and Chief Executive Officer of the Company
The Board of Cigma Metals Corporation(the "Company", "Cigma") (PINKSHEETS: CGMX) (FRANKFURT: C9KA) is pleased toannounce the appointment of Mr. Agustin Gomez de Segura as President andChief Executive Officer effective July 1, 2008 and the resignation of Mr.Lars Pearl as President, Chief Executive Officer and Director of theCompany. Mr. Lars Pearl...
- Next »
- page 1 of 82
- « Previous
Sort byClose
- Incorporated: 1985
- CEO: Mr. James C. Mullen
Biogen Idec is an international biotechnology company engaged in the development, manufacturing and commercialization of novel therapeutics for human healthcare. Co. currently market four products: AVONEX® for the treatment of relapsing forms of multiple sclerosis or MS; RITUXAN® for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphomas; TYSABRI® for the treatment of relapsing forms of MS in U.S. and other countries, and in U.S. for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease; and FUMADERM® for the treatment of severe psoriasis.
Key Competitors
Biogen Idec Inc. Company Info
Board of Directors
Mr. Bruce R. Ross
Chairman
Mr. Robert W. Pangia
Mr. William D. Young
Miss Nancy L. Leaming
Mr. James C. Mullen
Dr. Thomas F. Keller Ph.D.
Ms. Lynn Schenk
Dr. Phillip A. Sharp Ph.D.
Dr. Cecil B. Pickett Ph.D.
Mr. Lawrence C. Best
Dr. Alan B. Glassberg
Contact Information
14 Cambridge Center
Cambridge, MA
617 679-2000
NAICS Code
Biological Product (except Diagnostic) Manufacturing: 325414Brought to you by IBMSponsored Resources
